HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

pyroxamide

inhibits histone deacetylase; structure in first source

Also Known As:

suberoyl-3-aminopyridineamide hydroxamic acid

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amines: 4871
  - Aminopyridines: 77
    - pyroxamide: 2
  - Hydroxylamines: 16
    - Hydroxamic Acids: 239
      - pyroxamide: 2
- Carboxylic Acids: 973
  - Hydroxy Acids: 94
    - Hydroxamic Acids: 239
      - pyroxamide: 2
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridines: 88
    - Aminopyridines: 77
      - pyroxamide: 2

Experts

1.	Butler, Lisa M: 1 article (11/2003)
2.	Coffey, Dennis C: 1 article (11/2003)
3.	Glick, Richard D: 1 article (11/2003)
4.	Kutko, Martha C: 1 article (11/2003)
5.	LaQuaglia, Michael P: 1 article (11/2003)
6.	Marks, Paul A: 1 article (11/2003)
7.	Richon, Victoria M: 1 article (11/2003)
8.	Rifkind, Richard A: 1 article (11/2003)
9.	Agus, D B: 1 article (04/2001)
10.	Breslow, R: 1 article (04/2001)

Related Diseases

1.	Rhabdomyosarcoma 11/15/2003 - "The effects of two of these agents, suberoylanilide hydroxamic acid (SAHA) and suberoyl-3-aminopyridineamide hydroxamic acid (pyroxamide), were investigated for their growth-suppressive effects on rhabdomyosarcoma (RMS) cells. "
2.	Neuroblastoma 04/01/2001 - "Pyroxamide, at micromolar concentrations, induced terminal differentiation in murine erythroleukemia (MEL) cells and caused growth inhibition by cell cycle arrest and/or apoptosis in MEL, prostate carcinoma, bladder carcinoma, and neuroblastoma cells. "
3.	Neoplasms (Cancer) 04/01/2001 - "The findings suggest that pyroxamide may be a useful agent for the treatment of malignancy and that induction of p21/WAF1 in transformed cells by pyroxamide may contribute to the antitumor effects of this agent." 04/01/2001 - "Despite the potent growth-inhibitory effects of pyroxamide in this tumor model, serum prostate-specific antigen levels in control versus pyroxamide-treated mice were not significantly different. " 04/01/2001 - "Human CWR22 prostate tumor xenografts from mice treated with pyroxamide (100 or 200 mg/kg/day) showed increased levels of histone acetylation and increased expression of the cell cycle regulator p21/WAF1, compared with tumors from vehicle-treated control animals. "
4.	Acute Erythroblastic Leukemia (Erythroleukemia) 04/01/2001 - "Pyroxamide, at micromolar concentrations, induced terminal differentiation in murine erythroleukemia (MEL) cells and caused growth inhibition by cell cycle arrest and/or apoptosis in MEL, prostate carcinoma, bladder carcinoma, and neuroblastoma cells. "
5.	Carcinoma (Carcinomatosis) 04/01/2001 - "Pyroxamide, at micromolar concentrations, induced terminal differentiation in murine erythroleukemia (MEL) cells and caused growth inhibition by cell cycle arrest and/or apoptosis in MEL, prostate carcinoma, bladder carcinoma, and neuroblastoma cells. "

Related Drugs and Biologics

1.	pyroxamide
2.	Cyclin-Dependent Kinase Inhibitor p21
3.	Prostate-Specific Antigen (Semenogelase)
4.	Histones (Histone)
5.	Vorinostat